Efforts by drug companies to streamline and improve the execution of clinical study designs-to counter mounting costs and shorten development times associated with bringing new drugs to market-are yielding positive benefits.
Efforts by drug companies to streamline and improve the execution of clinical study designs-to counter mounting costs and shorten development times associated with bringing new drugs to market-are yielding positive benefits, according to an assessment recently completed by the Tufts Center for the Study of Drug Development and reported in the September/October Tufts CSDD Impact Report.
According to Tufts CSDD, greater emphasis by drug sponsors on upfront planning and governance to assess and challenge protocol feasibility and new approaches to development, including facilitated review mechanisms and greater use of adaptive trial designs, are helping to improve data quality and success rates, while cutting costs. Other findings from the analysis, include the following:
Read the full release here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.